Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunovion's Dasotraline To Be Filed In US For ADHD Despite Uncertainties

Executive Summary

Sunovion is pressing ahead with plans for an FDA filing for its ADHD drug dasotraline in adult and children patients despite ongoing uncertainty over the drug's efficacy in the older grouping.

You may also be interested in...



Keeping Track: Busy August Ends With Approval For Doravirine, CRLs For Dasotraline And Waylivra

The latest drug development news and highlights from our US FDA Performance Tracker.

Sunovion Must Regroup After Setback With Dasotraline In ADHD

Sunovion must find a new path forward for its dasotraline in attention deficit/hyperactivity disorder (ADHD), following a complete response letter from the US FDA.

NLS Pharma Pins Hopes On Ex-Obesity Drug For ADHD

Emerging Company Profile: NLS Pharma wants to develop novel treatments for ADHD, sleep disorders and cognitive impairments. Its big hope is mazindol CR, for which it has just announced promising Phase II data. The firm explains what is next.

Topics

Related Companies

UsernamePublicRestriction

Register

AP007430

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel